Review Article

Nepal Journal of Neuroscience 2024;21(1):3-8

Neurogenomics contribution to neurodegenerative diseases

Olufunto Omodele Adeleye[1], Darasimi Racheal Olorunlowu[2], Joshua Ayodele Yusuf[3], Elizabeth Kehinde Opoola[4], Stephen Tunmise Akanbi[5], Segun Samson Akindokun[6].

[1,2,3,4,5] Department of Anatomy, Ladoke Akintola University of Technology, University of Nigeria

[6] Everight Diagnostic and Laboratory services.

Date of submission: 20th August 2023 Date of Acceptance: 6th February 2024 Date of publication: 15th May 2024

Abstract

Neurodegenerative diseases are a group of complex disorders that progressively impair the structure and function of the nervous system, resulting in debilitating symptoms and reduced quality of life for affected individuals. Over the past few decades, advances in the field of genomics have revolutionized our understanding of the underlying molecular mechanisms driving these disorders. Neurogenomics, the intersection of neuroscience and genomics, has emerged as a crucial discipline in unraveling the genetic and molecular underpinnings of neurodegenerative diseases. Neurogenomics focuses on deciphering the genetic variations that contribute to the susceptibility and progression of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. Advances in DNA sequencing technologies have enabled researchers to identify specific genetic mutations and variations that are associated with increased disease risk. By studying the genetic mutations involved in neurodegenerative diseases, neurogenomics has provided valuable insights into the underlying disease mechanisms. These insights have led to a deeper understanding of protein aggregation, mitochondrial dysfunction, inflammation, and other cellular processes implicated in disease progression. By harnessing the power of neurogenomics through further studies, researchers and clinicians are moving closer to the goal of effectively preventing, diagnosing, and treating neurodegenerative diseases, thus offering hope to millions of individuals affected by these challenging conditions.

Conclusion: Neurogenomics has emerged as a pivotal field in unraveling the complex interplay between genetics and neurobiology in neurodegenerative diseases. By dissecting the genetic architecture, elucidating molecular mechanisms, and paving the way for targeted therapies, neurogenomics offers new avenues for understanding, diagnosing, and ultimately treating these disorders.

Keywords: Neurogenomics, Neurodegenerative Diseases, Genetics, Precision-Medicine, Ethical Concern.

Introduction

Neurodegenerative diseases pose a significant challenge to global healthcare systems, as they lead to progressive and irreversible damage to the nervous system, resulting in debilitating cognitive and motor impairments[1,2]. These diseases, such as Alzheimer's disease, Parkinson's disease, and Amyotrophic lateral sclerosis (ALS), are characterized by the gradual deterioration of nerve cells, neural networks, and brain structures[3]. The adverse effects of neurodegenerative diseases encompass a wide range of symptoms, including memory loss, impaired movement control, and compromised communication skills, all of which significantly diminish an individual's quality of life[4,5]. According to the World Health Organization (WHO), an estimated 50 million people worldwide are affected by these diseases, with projections indicating an increase in their prevalence as the global population ages[6]. These adverse effects not only place an emotional and physical burden on patients and their families but also contribute to societal and economic strains due to the high costs of care and lost productivity[7].

The impact of neurodegenerative diseases extends beyond individual patients, affecting families, caregivers, and healthcare systems. Alzheimer's disease, for instance, is the most common neurodegenerative disorder, causing memory loss, cognitive decline, and behavioral changes[8]. The adverse effects of neurodegenerative diseases on healthcare systems are substantial. As these diseases have no cure and only limited treatments to manage symptoms, patients often require long-term care and specialized interventions[9]. Consequently, addressing the adverse effects of neurodegenerative diseases necessitates a multi-faceted approach, encompassing not only improved medical interventions but also enhanced caregiver support, public awareness campaigns, and increased research funding[10].

However, Neurogenomics has emerged as a pivotal field at the intersection of genomics and neuroscience, revolutionizing the studies of neurodegenerative diseases.

Access this article online

Website: https://www.nepjol.info/index.php/NJN

DOI: https://doi.org/10.3126/njn.v21i1.58673

HOW TO CITE
Adeleye OO, Olorunlowu DR, Yusuf JA, Akanbi ST, Opoola EK, Akindokun SS. Neurogenomics contribution to neurodegenerative Diseases. NJNS. 2024;21(1):3-8

Address for correspondence:
Darasimi Racheal Olorunlowu
Department of Anatomy, Ladoke Akintola University of Technology, University of Nigeria
E-mail: olorunlowudarasimi@gmail.com

ISSN: 1813-1948 (Print), 1813-1956 (Online)

Through extensive genomic analysis, it has provided unprecedented insights into the genetic underpinnings of disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)[11;12]. The identification of disease-associated genes and variations has enabled researchers to unravel intricate molecular mechanisms, paving the way for more accurate diagnoses, personalized treatments, and potential therapeutic targets[13]. Neurogenomics has also facilitated the development of biomarkers for early detection and monitoring disease progression, enhancing our ability to intervene before irreversible damage occurs. With its comprehensive genetic perspective, neurogenomics is playing an instrumental role in advancing our comprehension of neurodegenerative diseases, fostering a more targeted approach towards prevention and treatment[14].

The amalgamation of neurogenomics with advanced technologies, such as next-generation sequencing and bioinformatics tools, has propelled the discovery of genetic variations associated with neurodegenerative disorders[15]. Genome-wide association studies (GWAS) have uncovered a multitude of susceptibility loci, providing valuable insights into the intricate interplay between genetic predisposition and environmental factors in disease development[16]. This comprehensive genomic approach has laid the foundation for the development of innovative therapies, including gene therapies and precision medicine strategies, tailored to individuals based on their unique genetic profiles[17].

GENETIC INSIGHTS IN NEURODEGENERATIVE DISEASES

Neurogenomics sheds light on the genetic risk factors associated with neurodegenerative diseases, providing crucial insights into disease risk, pathogenesis, and potential therapeutic strategies[18]. Its research involves the identification of specific genes associated with an increased susceptibility to neurodegenerative diseases[19]. For instance, the discovery of mutations in the APP, PSEN1, and PSEN2 genes has provided key insights into the development of early-onset Alzheimer's disease[20]. In addition to mutations, variations in certain genes are linked to a higher risk of developing neurodegenerative disorders[21]. Genome-wide association studies (GWAS) scan the entire genome for common genetic variants associated with disease risk. By analyzing large datasets of genetic information, researchers have identified numerous genetic loci associated with conditions like Parkinson's disease, allowing for a more comprehensive understanding of the genetic factors involved[22].

Neurogenomics investigates how genes are expressed and regulated in the nervous system under normal and disease conditions[23]. Alterations in gene expression profiles can highlight key molecular pathways that are disrupted in neurodegenerative diseases. This knowledge contributes to a deeper understanding of disease mechanisms and potential targets for therapeutic intervention[24]. Furthermore, genetic insights from neurogenomics enable the development of genetic tests that can predict an individual's risk of developing certain neurodegenerative diseases. These tests can aid in early diagnosis, allowing individuals to take preventive measures and make informed decisions about their health[25]. Genetic counseling helps individuals and families understand the implications of genetic findings and provides guidance on managing disease risk. These genetic findings enable healthcare professionals to assess an individual's genetic predisposition to the disease and potentially initiate preventive measures[26].

Ultimately, genetic insights garnered through neurogenomics provide a comprehensive understanding of the genetic basis of neurodegenerative diseases. By identifying risk genes, deciphering disease mechanisms, and uncovering genetic heterogeneity, researchers can tailor interventions, develop targeted therapies, and enhance early detection strategies[18]. This knowledge ultimately empowers medical professionals to offer personalized care and improve the quality of life for individuals affected by neurodegenerative diseases [26].

PRECISION MEDICINE AND THERAPIES IN NEURODEGENERATIVE DISEASES

Neurogenomics has also contributed greatly to the treatment of neurodegenerative diseases as it paves the way for personalized medicine approaches by tailoring treatments to an individual's genetic profile[27;12]. It aids in developing targeted therapies that address specific genetic pathways and interactions implicated in neurodegeneration. Advances in gene editing technologies offer potential avenues for correcting disease-causing mutations, while genetic biomarkers aid in early diagnosis and monitoring of disease progression[28]. This personalized approach enhances the effectiveness of treatments and improves patient outcomes[29].

Precision medicine, a personalized approach to healthcare, is revolutionizing the field of neurodegenerative diseases by tailoring treatments based on an individual's genetic profile, molecular characteristics, and environmental factors[26;12]. Neurogenomics plays a pivotal role in driving precision medicine strategies for these complex and devastating conditions. It does this by analyzing an individual's genetic makeup to identify specific genetic variations and mutations associated with neurodegenerative diseases[30]. This genetic information offers insights into disease risk, progression, and potential treatment responses[30]. Genetic biomarkers associated with neurodegenerative diseases can be used for early diagnosis, monitoring disease progression, and predicting treatment outcomes. These biomarkers help healthcare professionals make informed decisions about treatment strategies[31].

Precision medicine enables the development of therapies that target specific genetic mutations or disease-causing mechanisms[32]. For example, in cases of Huntington's disease, where the huntingtin gene mutation leads to protein aggregation, researchers are exploring treatments that aim to prevent or clear these aggregates[33]. Understanding the genetic basis of neurodegenerative diseases guides the design of drugs that selectively target the molecular pathways involved. This approach minimizes side effects and enhances treatment efficacy[24]. Another medical precision approach of neurogenomics in neurodegenerative diseases is the use of Gene Editing Technologies[34]. Neurogenomics has paved the way for gene editing technologies like CRISPR-Cas[9]. These tools offer the potential to correct disease-causing genetic mutations directly at the DNA level[35].

Precision medicine also allows for the identification of patient subgroups with similar genetic profiles. This

stratification enhances clinical trial design, enabling researchers to test therapies on individuals who are more likely to respond positively[36]. Genetic information obtained through neurogenomics can provide insights into disease prognosis and progression[37]. For individuals identified as genetically predisposed to neurodegenerative diseases, precision medicine offers the opportunity to implement lifestyle changes and interventions that reduce disease risk or delay onset. This approach increases the likelihood of detecting treatment effects and expedites drug development[38].

Evidently, precision medicine and therapies are transforming the landscape of neurodegenerative diseases by harnessing the power of neurogenomics[39]. By tailoring treatments to an individual's genetic and molecular characteristics, precision medicine holds the promise of more effective interventions, improved patient outcomes, and a brighter future for those affected by these challenging conditions[40].

NOVEL TARGETS AND RESEARCH TOOLS IN NEURODEGENERATIVE DISEASES

Neurogenomics has significantly contributed to the identification of novel therapeutic targets and the development of innovative research tools for investigating neurodegenerative diseases[41]. These advancements have the potential to revolutionize our understanding of disease mechanisms and facilitate the development of new treatments[42]. Animal models with genetically engineered mutations provide valuable tools for studying disease mechanisms and testing potential treatments. This information guides the development of innovative drugs designed to halt or slow down disease progression43. Through large-scale genetic studies, researchers are gaining insights into why certain individuals are more susceptible to neurodegenerative diseases than others[44].

Furthermore, neurogenomics research has paved the way for the development of advanced diagnostic tools[45]. Precision medicine approaches, which take into account an individual's genetic makeup, are being explored for tailoring diagnostic strategies[46]. Biomarker identification through genomic analysis of patient samples, such as cerebrospinal fluid or blood, can enable accurate disease detection and tracking of progression[47]. These tools offer the potential for earlier and more accurate diagnoses, facilitating timely interventions and personalized treatment plans that may slow down disease advancement[48].

In the realm of therapeutic innovation, neurogenomics holds significant promise. To facilitate advancements in neurodegenerative disease research, innovative genomic tools and technologies are being developed[49]. For instance, the advent of induced pluripotent stem cells (iPSCs) has enabled the generation of patient-specific neuronal models, allowing researchers to study disease mechanisms in a dish[50]. This approach not only provides insights into disease pathology but also serves as a platform for drug screening and personalized medicine[50]. Furthermore, the rise of single-cell transcriptomics has illuminated the heterogeneity of neuronal populations, uncovering subtypes that might be differentially affected in various diseases[51]. This knowledge could lead to the development of targeted therapies tailored to specific cell types[52]. Advanced imaging techniques, such as high-resolution microscopy, have also provided unprecedented views of molecular and cellular processes in the brain, aiding in the identification of biomarkers and the tracking of disease progression[53].

With a better understanding of the genetic and molecular mechanisms underlying neurodegenerative diseases, researchers can identify potential drug targets and develop more effective treatments[54]. Gene therapy approaches, utilizing techniques like CRISPR-Cas9, are being explored to correct or modulate disease-associated genetic mutations[55]. Additionally, the field of RNA therapeutics is gaining traction, aiming to modify gene expression and protein production through RNA-based molecules[56]. Neurogenomics-driven research is also contributing to the development of preclinical disease models that mimic the genetic complexities of human neurodegenerative diseases, enabling researchers to test potential therapies in a more relevant context[23].

Overall, neurogenomics has ushered in a new era of understanding and combating neurodegenerative diseases[57]. By unraveling the genetic basis of these disorders, researchers are not only uncovering key insights into disease mechanisms but also paving the way for the development of cutting-edge diagnostic tools and innovative therapeutic strategies[58]. As technology continues to advance, the integration of neurogenomics with other fields such as neuroimaging, bioinformatics, and functional genomics holds the potential to transform our ability to prevent, diagnose, and treat neurodegenerative diseases effectively48.

INCREMENT OF ETHICAL CONCERNS IN NEURODEGENERATIVE DISEASES

Neurogenomics has greatly improved our understanding of the genetic underpinnings of neurodegenerative diseases[59]. Identifying specific genetic variants associated with these conditions enables earlier detection and more accurate diagnosis, enabling personalized treatment plans[59]. However, ethical concerns arise in terms of informed consent, data privacy, and potential discrimination based on genetic predisposition[60]. Researchers and clinicians must ensure that individuals are fully informed about the implications of genetic testing, potential results, and the use of their data, while safeguarding against any potential misuse[61].

The ethical considerations surrounding access to treatments and interventions derived from neurogenomic research are paramount[62]. As potential therapies targeting specific genetic components of neurodegenerative diseases emerge, equitable distribution and affordability of these treatments become ethical imperatives[63]. Ensuring that these interventions are accessible to individuals across various socio-economic backgrounds and geographical locations promotes justice in healthcare[64]. Moreover, careful assessment of the benefits, risks, and uncertainties associated with these treatments is essential to avoid undue hype and ensure that patients and their families can make well-informed decisions[64].

The privacy of genetic information obtained through neurogenomics is a pressing ethical concern[65]. Advances in technology and data sharing have enabled large-scale genetic studies, but they also raise concerns about data security and potential breaches[66]. Safeguarding individuals' genetic information is vital to prevent unauthorized access, potential

discrimination by employers or insurance companies, and the misuse of sensitive data[67]. Robust data encryption, strict access controls, and clear consent procedures are essential to protect the privacy of individuals who contribute their genetic information to research efforts[67].

Ethical guidelines emphasize the importance of providing accurate, unbiased, and understandable information during genetic counseling sessions[68]. This supports individuals in making autonomous decisions about whether to undergo testing, how to interpret the results, and whether to share their genetic information with family members[68]. However, it may be considered that ethical contributions of neurogenomics extend to fostering informed decision-making for individuals and families affected by neurodegenerative diseases[69]. Genetic testing and counseling empower individuals with knowledge about their risks and potential outcomes, allowing them to plan for their future and make choices aligned with their values[69].

To sum up, the field of neurogenomics holds immense promise in advancing our understanding and treatment of neurodegenerative diseases[70]. However, it also presents a range of ethical considerations that must be carefully addressed to ensure responsible and equitable application[65]. Balancing the potential benefits of genetic insights with the need to protect individual privacy, ensure access to treatments, and promote informed decision-making is vital for harnessing the full potential of neurogenomics in the context of neurodegenerative diseases[71].

Conclusion

Neurogenomics has provided invaluable insights into the understanding of neurodegenerative diseases. These diseases are characterized by the progressive loss of neurons and cognitive functions. Neurogenomics has significantly contributed to unraveling the genetic basis of these conditions. Genome-wide association studies (GWAS) have been instrumental in identifying specific genetic variants associated with increased susceptibility to neurodegenerative disorders. These findings have shed light on potential risk factors and pathways implicated in disease development. Furthermore, advances in sequencing technologies have enabled the identification of rare genetic mutations that directly cause certain familial forms of these diseases. Precision medicine, another area impacted by neurogenomics, aims to tailor treatments based on an individual's genetic makeup, enhancing efficacy and reducing adverse effects. Neurogenomics has also improved our comprehension of disease mechanisms. These insights have guided the development of targeted therapies, and their contributions hold immense promise for future breakthroughs in preventing, diagnosing, and treating neurodegenerative conditions.

Reference

1. Wareham LK, Liddelow SA, Temple S, Benowitz LI, Di Polo A, Wellington C, Calkins DJ. Solving neurodegeneration: Common mechanisms and strategies for new treatments. Mol Neurodegener. 2022;17(1):23. https://doi.org/10.1186/s13024-021-00501-6
2. Babazadeh A, Vahed FM, Jafari SM. Nanocarrier-mediated brain delivery of bioactives for treatment/prevention of neurodegenerative diseases. J Control Release. 2020;321:211-221. https://doi.org/10.1016/j.jconrel.2020.06.049
3. Kori M, Aydın B, Unal S, Arga KY, Kazan D. Metabolic biomarkers and neurodegeneration: a pathway enrichment analysis of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Omics J Integr Biol. 2016;20(11):645-661. https://doi.org/10.1089/omi.2016.0130
4. Colwell CS. Defining circadian disruption in neurodegenerative disorders. J Clin Invest. 2021;131(19). https://doi.org/10.1172/JCI151788
5. Sirin S, Dolanbay SN, Aslim B. Role of plant-derived alkaloids as antioxidant agents for neurodegenerative diseases. Health Sci Rev. 2022;100071. https://doi.org/10.1016/j.hsr.2022.100071
6. World Health Organization (WHO). Global action plan on the public health response to dementia 2017-2025. https://www.who.int/mental_health/neurology/dementia/action_plan_2017_2025/en/ Published 2020. Accessed [Date].
7. Alzheimer's Association. 2021 Alzheimer's disease facts and figures. [Internet]. Available from: https://www.alz.org/alzheimer's-dementia/facts-figures
8. Lamptey RN, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022;23(3):1851. https://doi.org/10.3390/ijms23031851
9. Newberg AB, Serruya M, Wintering N, Moss AS, Reibel D, Monti DA. Meditation and neurodegenerative diseases. Ann N Y Acad Sci. 2014;1307(1):112-123. https://doi.org/10.1111/nyas.12385
10. Geldenhuys WJ, Van der Schyf CJ. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2013;8(2):115-129. https://doi.org/10.1517/17460441.2013.752358
11. Hoischen A, Krumm N, Eichler EE. Prioritization of neurodevelopmental disease genes by discovery of new mutations. Nat Neurosci. 2014;17(6):764-772. https://doi.org/10.1038/nn.3710
12. Hampel HOBS, O'Bryant SE, Castrillo JI, Ritchie C, Rojkova K, Broich K, Benda N, Nisticò R, Frank RA, Dubois B, Escott-Price V, Lista S. Precision medicine-the golden gate for detection, treatment and prevention of Alzheimer's disease. J Prev Alzheimers Dis. 2016;3(4):243. https://doi.org/10.14283/jpad.2016.120
13. Senthil J, Meena M, IGNACY A, Ramanathan T. Advances in Precision Medicine: Current Landscape and Future Directions. Latin Am J Pharm. 2023;42(3):1204-1211.
14. Jain KK, Jain KK. Principles of Management of Drug-Induced Neurological Disorders. In: Drug-induced Neurological Disorders. 2021:79-87. https://doi.org/10.1016/B978-0-12-819562-8.00007-0
15. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. https://doi.org/10.15252/emmm.201606210
16. Fernandez-Santiago R, Iranzo A, Gaig C, Serradell M,

Fernández M, Tolosa E, Santamaría J. Microarray analysis of brainstem mRNA in Parkinson's disease patients with REM sleep behavior disorder. Eur J Neurosci. 2015;42(3):1994-2006. https://doi.org/10.1111/ejn.13007
17. Taylor JP, Brown RH, Cleveland DW. Decoding ALS: From genes to mechanism. Nature. 2016;539(7628):197-206. https://doi.org/10.1038/nature20413
18. Nikom D, Zheng S. Alternative splicing in neurodegenerative disease and the promise of RNA therapies. Nat Rev Neurosci. 2023;1-17. https://doi.org/10.1038/s41583-023-00661-0
19. Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693-714. https://doi.org/10.1016/j.cell.2023.01.023
20. Bai B, Vanderwall D, Li Y, Wang X, Poudel S, Wang H, Dey KK, Chen PC, Yang K, Peng J. Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery. Mol Neurodegener. 2021;16(1):55. https://doi.org/10.1186/s13024-021-00465-9
21. Jay TR, von Saucken VE, Landreth GE. TREM2 in neurodegenerative diseases. Mol Neurodegener. 2017;12(1):1-33. https://doi.org/10.1186/s13024-017-0197-5
22. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Rizig M. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-1102. https://doi.org/10.1016/S1474-4422(19)30320-5
23. Afrasiabi A, Keane JT, Heng JIT, Palmer EE, Lovell NH, Alinejad-Rokny H. Quantitative neurogenetics: applications in understanding disease. Biochem Soc Trans. 2021;49(4):1621-1631. https://doi.org/10.1042/BST20200870
24. Parikshak NN, Gandal MJ, Geschwind DH. Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat Rev Genet. 2015;16(8):441-458. https://doi.org/10.1038/nrg3934
25. de Lara AM, Núñez-Acosta E, Saruwatari-Zavala G, Soto-Gómez L, Rentería ME. Ethical, legal and social implications of susceptibility genetic testing for late-onset neurodegenerative diseases. 2018.
26. Strianese O, Rizzo F, Ciccarelli M, Galasso G, D'Agostino Y, Salvati A, Del Giudice C, Tesorio P, Rusciano MR. Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes. 2020;11(7):747. https://doi.org/10.3390/genes11070747
27. Hampel H, Vergallo A, Perry G, Lista S, Alzheimer Precision Medicine Initiative. The Alzheimer precision medicine initiative. J Alzheimers Dis. 2019;68(1):1-24. https://doi.org/10.3233/JAD-181121
28. Arafah A, Khatoon S, Rasool I, Khan A, Rather MA, Abujabal KA, Faqih YAH, Rashid H, Rashid SM, Bilal Ahmad S, Alexiou A, Rehman MU. The potential of precision medicine approaches for the treatment and prevention of Alzheimer's disease. Biomedicines. 2023;11(2):335. https://doi.org/10.3390/biomedicines11020335
29. Zhai K, Yousef MS, Mohammed S, Al-Dewik NI, Qoronfleh MW. Optimizing clinical workflow using precision medicine and advanced data analytics. Processes. 2023;11(3):939. https://doi.org/10.3390/pr11030939
30. Deal SL, Yamamoto S. Unraveling novel mechanisms of neurodegeneration through a large-scale forward genetic screen in Drosophila. Front Genet. 2019;9:700. https://doi.org/10.3389/fgene.2018.00700
31. Jakubowski JL, Labrie V. Epigenetic biomarkers for Parkinson's disease: from diagnostics to therapeutics. J Parkinsons Dis. 2017;7(1):1-12. https://doi.org/10.3233/JPD-160965
32. Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov. 2018;17(3):183-196. https://doi.org/10.1038/nrd.2017.226
33. Jarosińska OD, Rüdiger SG. Molecular strategies to target protein aggregation in Huntington's disease. Front Mol Biosci. 2021;8:1068. https://doi.org/10.3389/fmolb.2021.758460
34. Rittiner JE, Moncalvo M, Chiba-Falek O, Kantor B. Gene-editing technologies paired with viral vectors for translational research into neurodegenerative diseases. Front Mol Neurosci. 2020;13:148. https://doi.org/10.3389/fnmol.2020.00148
35. Karwacka M, Olejniczak M. Advances in modeling polyglutamine diseases using genome editing tools. Cells. 2022;11(3):517. https://doi.org/10.3390/cells11030517
36. Gligorijević V, Malod-Dognin N, Pržulj N. Integrative methods for analyzing big data in precision medicine. Proteomics. 2016;16(5):741-758. https://doi.org/10.1002/pmic.201500396
37. Hall A, Bandres-Ciga S, Diez-Fairen M, Quinn JP, Billingsley KJ. Genetic risk profiling in Parkinson's disease and utilizing genetics to gain insight into disease-related biological pathways. Int J Mol Sci. 2020;21(19):7332. https://doi.org/10.3390/ijms21197332
38. Strafella C, Caputo V, Galota MR, Zampatti S, Marella G, Mauriello S, Cascella R, Giardina E. Application of precision medicine in neurodegenerative diseases. Front Neurol. 2018;9:701. https://doi.org/10.3389/fneur.2018.00701
39. Geschwind DH, Gleeson JG. Editorial overview: Neurodevelopment Diseases and Neurogenetics pivot towards mechanisms and therapies. Curr Opin Genet Dev. 2020;65:iii-vii. https://doi.org/10.1016/j.gde.2020.04.007
40. Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. Obstet Gynecol Surv. 2015;70(10):612-614. https://doi.org/10.1097/OGX.0000000000000298
41. Atkinson PJ, Swami M, Ridgway N, Roberts M, Kinghorn J, Warner TT, Staddon JM, Takle AK. Advancing novel therapies for neurodegeneration through an innovative model for industry–academia collaborations: A decade of the Eisai–UCL experience. Drug Discov Today. 2023;103732. https://doi.org/10.1016/j.drudis.2023.103732
42. Schubert CR, O'Donnell P, Quan J, Wendland JR, Xi HS, Winslow AR, Domenici E, Essioux L, Kam-Thong T, Airey DC, Calley JN, Weinberger DR. BrainSeq: neurogenomics to drive novel target discovery for neuropsychiatric disorders. Neuron. 2015;88(6):1078-1083. https://doi.org/10.1016/j.neuron.2015.11.035
43. Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances, and prospects. Signal Transduct Target Ther. 2020;5(1):1. https://

doi.org/10.1038/s41392-019-0063-7
44. Pihlstrøm L, Wiethoff S, Houlden H. Genetics of neurodegenerative diseases: an overview. Handb Clin Neurol. 2018;145:309-323. https://doi.org/10.1016/B978-0-444-63233-3.00020-3
45. Mesleh AG, Abdulla SA, El-Agnaf O. Paving the way toward personalized medicine: current advances and challenges in multi-OMICS approach in autism spectrum disorder for biomarkers discovery and patient stratification. J Pers Med. 2021;11(1):41. https://doi.org/10.3390/jpm11010041
46. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018;109(6):952-963. https://doi.org/10.1016/j.fertnstert.2018.05.006
47. Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson's disease: Advances and strategies. Parkinsonism Relat Disord. 2016;22:S106-S110. https://doi.org/10.1016/j.parkreldis.2015.09.004
48. Jain KK, Jain KK. Personalized Therapy of Neurological Disorders. In: Textbook of Personalized Medicine. 2021:213-262. https://doi.org/10.1007/978-981-10-5989-5_10
49. Bordoni M, Rey F, Fantini V, Pansarasa O, Di Giulio AM, Carelli S, Cereda C. From neuronal differentiation of iPSCs to 3D neuro-organoids: Modelling and therapy of neurodegenerative diseases. Int J Mol Sci. 2018;19(12):3972. https://doi.org/10.3390/ijms19123972
50. Li H, Jiang H, Zhang B, Feng J. Modeling Parkinson's disease using patient-specific induced pluripotent stem cells. J Parkinson's Dis. 2018;8(4):479-493. https://doi.org/10.3233/JPD-181464
51. Luquez T, Gaur P, Kosater IM, Lam M, Lee DI, Mares J, Paryani F, Yadav A, Menon V. Cell type-specific changes identified by single-cell transcriptomics in Alzheimer's disease. Genome Med. 2022;14(1):136. https://doi.org/10.1186/s13073-022-01122-5
52. Tasic B. Single cell transcriptomics in neuroscience: cell classification and beyond. Curr Opin Neurobiol. 2018;50:242-249. https://doi.org/10.1016/j.conb.2018.04.020
53. Razansky D, Klohs J, Ni R. Multi-scale optoacoustic molecular imaging of brain diseases. Eur J Nucl Med Mol Imaging. 2021;1-19. https://doi.org/10.1007/s00259-021-05578-1
54. Myszczynska MA, Ojamies PN, Lacoste AM, Neil D, Saffari A, Mead R, Hautbergue GM, Holbrook JD, Ferraiuolo L. Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. Nat Rev Neurol. 2020;16(8):440-456. https://doi.org/10.1038/s41582-020-0385-5
55. Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK, Kumar P, Ambasta RK, Dureja H, Devkota HP, Gupta G, Jha NK. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics. J Adv Res. 2022;40:207-221. https://doi.org/10.1016/j.jare.2021.09.007
56. Anthony K. RNA-based therapeutics for neurological diseases. RNA Biol. 2022;19(1):176-190. https://doi.org/10.1080/15476286.2021.2019718
57. Bartesaghi R, Vicari S, Mobley WC. Prenatal and postnatal pharmacotherapy in Down syndrome: the search to prevent or ameliorate neurodevelopmental and neurodegenerative disorders. Annu Rev Pharmacol Toxicol. 2022;62:211-233. https://doi.org/10.1146/annurev-pharmtox-020520-122727
58. Diaz-Beltran L, Cano C, Wall DP, Esteban FJ. Systems biology as a comparative approach to understand complex gene expression in neurological diseases. Behav Sci. 2013;3(2):253-272. https://doi.org/10.3390/bs3020253
59. Begum R. Translating neurogenomics: deconvoluting complex brain disorders. Genome Med. 2018;10:1-2. https://doi.org/10.1186/s13073-017-0513-5
60. Manrique de Lara A, Soto-Gómez L, Núñez-Acosta E, Saruwatari-Zavala G, Rentería ME. Ethical issues in susceptibility genetic testing for late-onset neurodegenerative diseases. Am J Med Genet Part B Neuropsychiatr Genet. 2019;180(8):609-621. https://doi.org/10.1002/ajmg.b.32735
61. Jwa AS, Poldrack RA. Addressing privacy risk in neuroscience data: from data protection to harm prevention. J Law Biosci. 2022;9(2):lsac025. https://doi.org/10.1093/jlb/lsac025
62. Mezinska S, Gallagher L, Verbrugge M, Bunnik EM. Ethical issues in genomics research on neurodevelopmental disorders: a critical interpretive review. Hum Genomics. 2021;15(1):1-14. https://doi.org/10.1186/s40246-020-00313-3
63. van Eeghen AM, Bruining H, Wolf NI, Bergen AA, Houtkooper RH, van Haelst MM, van Karnebeek CD. Personalized medicine for rare neurogenetic disorders: can we make it happen? Mol Case Stud. 2022;8(2):a006200. https://doi.org/10.1016/j.omcs.2022.a006200
64. Adachi T, El-Hattab AW, Jain R, Nogales Crespo KA, Quirland Lazo CI, Scarpa M, Summar M, Wattanasirichaigoon D. Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges. Int J Environ Res Public Health. 2023;20(6):4732. https://doi.org/10.3390/ijerph20064732
65. Esmonde K, Roth S, Walker A. A social and ethical framework for providing health information obtained from combining genetics and fitness tracking data. Technol Soc. 2023;102297. https://doi.org/10.1016/j.techsoc.2023.102297
66. Dove ES. Biobanks, data sharing, and the drive for a global privacy governance framework. J Law Med Ethics. 2015;43(4):675-689. https://doi.org/10.1111/jlme.12314
67. Seaver LH, Khushf G, King NM, Matalon DR, Sanghavi K, Vatta M, Wees K, Social ACMG, Ethical and Legal Issues Committee. Points to consider to avoid unfair discrimination and the misuse of genetic information: A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022;24(3):512-520. https://doi.org/10.1016/j.gim.2021.11.012
68. Jamal L, Schupmann W, Berkman BE. An ethical framework for genetic counseling in the genomic era. J Genet Couns. 2020;29(5):718-727. https://doi.org/10.1002/jgc4.1323
69. Wang S, Jiang X, Singh S, Marmor R, Bonomi L, Fox D, Dow M, Ohno-Machado L. Genome privacy: challenges, technical approaches to mitigate risk, and ethical considerations in the United States. Ann N Y Acad Sci. 2017;1387(1):73-83. https://doi.org/10.1111/nyas.13330
70. Riva A, Golda A, Balagura G, Amadori E, Vari MS, Piccolo G, Iacomino M, Lattanzi S, Salpietro V, Minetti C, Striano P. New trends and most promising therapeutic strategies for epilepsy treatment. Front Neurol. 2021;12:753753. https://doi.org/10.3389/fneur.2021.753753
71. Morse SJ. Genetics and criminal justice. In: The Oxford Handbook of Molecular Psychology. Oxford: Oxford University Press; 2015. p. 409.